In a real-world multicenter study, amavantamab has demonstrated strong efficacy in NSCLC patients with atypical EGFR mutations like G719X, S768I and L861Q with an 85.7% clinical response rate and a 100% disease control rate [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.